Intra-putaminal muscarinic receptor agonist infusion induces a dystonic phenotype in non-human primates
- 24 July 2025
- journal article
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (12) , 4532-4547
Abstract
Dystonia is a debilitating motor disorder of unclear pathophysiology, for which no specific pharmacological treatment is available in most cases. So far, several genetic models of dystonia suggesting a potential dysregulation of the intrastriatal cholinergic system have been obtained in rodents. However, in most cases, these animals did not exhibit a clear phenotype of dystonia but less specific motor impairments. In this study, we engineered an original model of dystonia in non-human primates by increasing cholinergic tone in the sensorimotor striatum. Chronic infusion of oxotremorine, a non-selective muscarinic agonist, into the putamen of non-human primates led to abnormal postures and dystonic movements, supported by EMG recordings. These motor abnormalities were associated with striatal hypermetabolism and significant changes in the firing rate of external and internal pallidum neurons. Furthermore, the pattern of neuronal activity in the internal pallidum was disrupted, and low-frequency oscillatory activity emerged in local field potentials within this structure. These data directly demonstrate, for the first time, in non-human primates that putaminal cholinergic dysregulation plays a crucial role in the pathophysiology of dystonia by disrupting both striatopallidal pathways.Keywords
Funding Information
- French Agence Nationale de la Recherche
- Ministry of Research
- Centre National de la Recherche Scientifique (CNRS U3793)
- Fondation pour la Recherche Médicale (Equipe FRM EQU202203014688)
This publication has 69 references indexed in Scilit:
- Spiking Patterns in the Globus Pallidus Highlight Convergent Neural Dynamics across Diverse Genetic Dystonia SyndromesAnnals of Neurology, 2025
- Phenomenology and classification of dystonia: A consensus updateMovement Disorders, 2013
- Enhanced low‐frequency oscillatory activity of the subthalamic nucleus in a patient with dystoniaMovement Disorders, 2012
- Paroxysmal dyskinesias in miceMovement Disorders, 2008
- Reliability of the Burke‐Fahn‐Marsden scale in a multicenter trial for dystoniaMovement Disorders, 2007
- Rodent models for dystonia research: Characteristics, evaluation, and utilityMovement Disorders, 2005
- Neuronal globus pallidus activity in patients with generalised dystoniaMovement Disorders, 2003
- Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismusAnnals of Neurology, 1999
- Glutamate receptor agonists increase the expression of Fos, Fra, and AP‐1 DNA binding activity in the mammalian brainJournal of Neuroscience Research, 1989
- The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity.The EMBO Journal, 1989